skip to main content
Close Icon We use cookies to improve your website experience.  To learn about our use of cookies and how you can manage your cookie settings, please see our Cookie Policy.  By continuing to use the website, you consent to our use of cookies.
Global Search Configuration
  • Close Icon

UK_Brexit_Pharma_Intelligence

With less than three months to go before the UK is due to leave the EU, manufacturers based in any of the EU 27 countries (i.e, all of the EU countries not including the UK) are still finding it difficult to get their heads around the new demands that could be placed on them to continue marketing products in the UK in the event of a no-deal Brexit.

Terms of the UK leaving the EU have still not been agreed, and the scenario of no deal being reached between the EU and UK is looking increasingly likely. Internally, divided UK factions struggle to find any kind of agreement.

More from MHRA

For more details about the MHRA registration deadlines in the event of a no-deal Brexit see: Brexit At The 11th Hour: UK Refreshes No-Deal Guidance For Medtech

One of the requirements, as explained in the government's Jan. 3 document, "Further guidance note on the regulation of medicines, medical devices and clinical trials if there's no Brexit deal,"will be for EU 27 manufacturers to have a "Responsible Person" based in the UK. The responsibilities of this person will be similar to those of the European Authorized Representative under the EU medical device rules.

The guidance note, published by the UK Medicines and Healthcare products Regulatory Agency (MHRA), states that where a device manufacturer is not established in the UK, "registration of a product with the MHRA must be undertaken by a ‘UK Responsible Person’ established in the UK and with a UK registered address who will take responsibility for the product in the UK."

But there are still questions being voiced in industry over whether this ‘UK Responsible Person’ needs to be physically present in the UK. In response, the MHRA has told Medtech Insight that "there would need to be someone physically located within the UK."

The agency's full statement reads: “Whilst the UK Responsible Person may make use of resources based outside of the UK, there would need to be someone physically located within the UK for the MHRA to communicate with and they must provide an address which can be used for official communications. The UK Responsible Person must be contactable at the address provided and is obliged to keep certain information at the disposal of the MHRA, such as declarations of conformity and technical documentation."

EU Position

It is also worth pointing out that the European Commission made it clear in a  January 2018 notice to stakeholders that, under a no-deal scenario, businesses with an authorized representative based in the UK would need to establish a new authorized representative in an EU country if the companies want an representative to carry out tasks on their behalf within the EU.

From the editors of Clinica

 

おすすめのニュース&レポート

;

お問い合わせ&レポートストア

専任スタッフによるデモンストレーションを兼ねたサービスの詳しいご説明、または無料トライアルを常時受け付けています。ご希望の場合は下記のフォームよりお気軽にお申し込みください。

*一部のサービスでは無料トライアルをご利用になれません。

ご質問等ございましたらお気軽にご連絡下さい。

日本(平日:9時~18時)
電話:+81 (0)3 6273 4260
Email:inquiry.jp@informa.com

オンラインショップのレポートストアでは、医療用医薬品の市場調査・分析レポートを常時1000本以上販売しています。レポート1本単位で購入でき、オンラインでご提供いたします。

お探しの情報が見つからない場合はお問い合わせ先までお気軽にご連絡ください。